Global Information
회사소개 | 문의

세계의 혈당 모니터링 시스템 시장 예측

GLOBAL GLUCOSE MONITORING SYSTEM MARKET FORECAST 2018-2026

리서치사 Inkwood Research
발행일 2018년 07월 상품 코드 492797
페이지 정보 영문 169 Pages
가격
US $ 2,500 ₩ 2,848,500 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,418,200 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,127,300 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 혈당 모니터링 시스템 시장 예측 GLOBAL GLUCOSE MONITORING SYSTEM MARKET FORECAST 2018-2026
발행일 : 2018년 07월 페이지 정보 : 영문 169 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

세계의 혈당 모니터링 시스템(Glucose Monitoring System) 시장에 대해 조사했으며, 시장 구조, 시장 성장 촉진요인 및 저해요인, 연속혈당측정기(CGMS) 및 자가혈당측정(SMBG)의 컴포넌트·용도별 시장 동향, 경쟁 환경, 주요 기업 프로파일 등을 정리하여 전해드립니다.

제1장 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 개요

  • 시장 성장 촉진요인과 영향
  • 시장 성장 저해요인과 영향

제5장 연속혈당측정기(CGMS) 시장 : 컴포넌트별

  • 센서
  • 송수신기
  • 인슐린 펌프

제6장 연속혈당측정기(CGMS) 시장 : 용도별

  • 진료소
  • 병원
  • 재택의료

제7장 자가혈당측정(SMBG) 시장 : 컴포넌트별

  • 검사지
  • 혈당측정기
  • 기타

제8장 자가혈당측정(SMBG) 시장 : 용도별

  • 재택의료
  • 진료소
  • 병원

제9장 시장 분석

  • Five Forces 분석
  • 시장 동향
  • 주요 지역
  • 인수합병
  • 주요 동향

제10장 지역 분석

  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제11장 경쟁 환경

LSH 17.05.18

LIST OF TABLES

  • TABLE 1 GLOBAL CGMS MARKET BY GEOGRAPHY, 2018-2026($ MILLION)
  • TABLE 2 GLOBAL SMBG MARKET BY GEOGRAPHY, 2018-2026 ($ MILLION)
  • TABLE 3 DIABETES PREVALENCE IN VARIOUS GEOGRAPHIES 2015-2040 (MILLIONS)
  • TABLE 4 GLOBAL CGMS MARKET, BY COMPONENT TYPE, 2018-2026($ MILLION)
  • TABLE 5 GLOBAL CGMS SENSORS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 6 GLOBAL CGMS TRANSMITTERS AND RECEIVERS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 7 GLOBAL CGMS INSULIN PUMP MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 8 GLOBAL CGMS MARKET, BY END-USER 2018-2026 ($ MILLION)
  • TABLE 9 GLOBAL CGMS HOME SETTINGS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 10 GLOBAL CGMS DIAGNOSTICS AND CLINICAL MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 11 GLOBAL CGMS HOSPITAL MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 12 IMPORTANT ASPECTS FOR THE USE OF SMBG DEVICES IN HOME-CARE SETTINGS
  • TABLE 13 SMBG STRIPS USAGE SCENARIO IN SELECTED COUNTRIES IN AMERICAS
  • TABLE 14 PRODUCT MATRIX FOR LANCETS
  • TABLE 15 GLOBAL SMBG MARKET, BY COMPONENT TYPE, 2018-2026 ($ MILLION)
  • TABLE 16 GLOBAL SMBG LANCETS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 17 GLOBAL SMBG HOME SETTING MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 18 GLOBAL SMBG CLINICAL MARKET,BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 19 GLOBAL SMBG HOSPITALS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 20 GLOBAL SMBG MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 21 GLOBAL CGMS MARKET REVENUE, BY GEOGRAPHY 2018-2026($ MILLION)
  • TABLE 22 CONVERSION RATE USED FOR DIFFERENT CURRENCIES INTO DOLLAR
  • TABLE 23 NORTH AMERICA SMBG MARKET 2018-2026 ($ MILLION)
  • TABLE 24 NORTH AMERICA CGMS MARKET 2018-2026 ($ MILLION)
  • TABLE 25 EUROPE SMBG MARKET 2018-2026 ($ MILLION)
  • TABLE 26 EUROPE CGMS MARKET 2018-2026 ($ MILLION)
  • TABLE 27 GERMANY DIABETIC STATISTICS 2015
  • TABLE 28 AVERAGE PRICES IN GERMANY FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
  • TABLE 29 GERMANY SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 30 AVERAGE PRICES IN UK FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
  • TABLE 31 UNITED KINGDOM SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 32 ASIA-PACIFIC SMBG MARKET REVENUE 2018-2026($ MILLION)
  • TABLE 33 AVERAGE PRICES IN CHINA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
  • TABLE 34 CHINA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 35 AVERAGE PRICES IN INDIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 36 INDIA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 37 AVERAGE PRICES IN AUSTRALIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 38 AUSTRALIA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 39 AVERAGE PRICES IN JAPAN FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 40 JAPAN SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 41 AVERAGE PRICES IN SOUTH KOREA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 42 SOUTH KOREA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 43 AVERAGE PRICES IN INDONESIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 44 INDONESIA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 45 AVERAGE PRICES IN MALAYSIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 46 MALAYSIA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 47 AVERAGE PRICES IN PHILIPPINES FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 48 PHILIPPINES SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 49 AVERAGE PRICES IN THAILAND FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 50 THAILAND SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 51 AVERAGE PRICES IN VIETNAM FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 52 VIETNAM SMBG SALES CHANNEL 2018-2026 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL CGMS SENSORS MARKET, 2018-2026($ MILLION)
  • FIGURE 2 GLOBAL CGMS TRANSMITTERS AND RECEIVERS MARKET, 2018-2026($ MILLION)
  • FIGURE 3 GLOBAL CGMS INSULIN PUMP MARKET, 2018-2026($ MILLION)
  • FIGURE 4 GLOBAL CGMS SHARE, BY END-USER 2017 & 2026 (%)
  • FIGURE 5 GLOBAL CGMS HOME SETTING MARKET, 2018-2026($ MILLION)
  • FIGURE 6 GLOBAL CGMS DIAGNOSTICS AND CLINICAL MARKET, 2018-2026($ MILLION)
  • FIGURE 7 GLOBAL CGMS HOSPITAL MARKET, 2018-2026($ MILLION)
  • FIGURE 8 GLOBAL SMBG MARKET SHARE, BY COMPONENT TYPE 2017 & 2026(%)
  • FIGURE 9 GLOBAL SMBG TEST STRIPS MARKET, 2018-2026 ($ MILLION)
  • FIGURE 10 GLOBAL SMBG TEST STRIPS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • FIGURE 11 GLOBAL SMBG GLUCOSE METER MARKET, 2018-2026 ($ MILLION)
  • FIGURE 12 GLOBAL SMBG GLUCOSE METER MARKET,BY GEOGRAPHY 2018-2026 ($ MILLION)
  • FIGURE 13 GLOBAL SMBG LANCETS MARKET, 2018-2026 ($ MILLION)
  • FIGURE 14 GLOBAL SMBG MARKET SHARE, BY END-USER 2017& 2026 (%)
  • FIGURE 15 GLOBAL SMBG HOME SETTING MARKET, 2018-2026 ($ MILLION)
  • FIGURE 16 GLOBAL SMBG CLINICAL MARKET, 2018-2026 ($ MILLION)
  • FIGURE 17 GLOBAL SMBG HOSPITALS MARKET, 2018-2026 ($ MILLION)
  • FIGURE 18 GLOBAL GGMS MARKET SHARE, BY GEOGRAPHY 2017 & 2026 (%)
  • FIGURE 19 NORTH AMERICA CGMS MARKET SHARE, BY COUNTRY 2017 & 2026 (%)
  • FIGURE 20 US CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 21 US SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 22 CANADA CGMS MARKET REVENUE, 2018-2026 ($ MILLION)
  • FIGURE 23 CANADA SMBG MARKET REVENUE, 2018-2026 ($ MILLION)
  • FIGURE 24 EUROPE CGMS MARKET SHARE, BY COUNTRY 2017 & 2026 (%)
  • FIGURE 25 GERMANY CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 26 GERMANY SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 27 UK CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 28 UK SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 29 FRANCE CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 30 FRANCE SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 31 ITALY CGMS MARKET REVENUE 2018-2026($ MILLION)
  • FIGURE 32 ITALY SMBG MARKET REVENUE 2018-2026($ MILLION)
  • FIGURE 33 SPAIN CGMS MARKET REVENUE 2018-2026($ MILLION)
  • FIGURE 34 SPAIN SMBG MARKET REVENUE 2018-2026($ MILLION)
  • FIGURE 35 RUSSIA CGMS MARKET REVENUE 2018-2026($ MILLION)
  • FIGURE 36 RUSSIA SMBG MARKET REVENUE 2018-2026($ MILLION)
  • FIGURE 37 REST OF EUROPE (ROE) CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 38 REST OF EUROPE (ROE) SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 39 ASIA-PACIFIC CGMS MARKET REVENUE 2018-2026($ MILLION)
  • FIGURE 40 CHINA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 41 CHINA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 42 INDIA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 43 INDIA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 44 AUSTRALIA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 45 AUSTRALIA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 46 DEATHS IN AUSTRALIA DUE TO DIABETES
  • FIGURE 47 JAPAN CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 48 JAPAN SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 49 SOUTH KOREA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 50 SOUTH KOREA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 51 INDONESIA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 52 INDONESIA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 53 MALAYSIA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 54 MALAYSIA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 55 PHILIPPINES CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 56 PHILIPPINES SMBG MARKET REVENUE, 2018-2026 ($ MILLION)
  • FIGURE 57 THAILAND CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 58 THAILAND SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 59 VIETNAM CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 60 VIETNAM SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 61 REST OF ASIA-PACIFIC CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 62 REST OF ASIA-PACIFIC SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 63 LATIN AMERICA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 64 LATIN AMERICA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 65 MEA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 66 MEA SMBG MARKET REVENUE, 2018-2026($ MILLION)

KEY FINDINGS

The Global Continuous Glucose Monitoring System (CGMS) market stood at $1120 million in 2017. Over the forecast years of 2018-2026, the market is expected to rise at a 32.94% CAGR, generating a net total of $14519.3 million.

Similarly, the Self-monitoring of Blood Glucose (SMBG) market stood at $13192.2 million in 2017. Over the forecast years of 2018-2026, the market is expected to rise at a 7.57% CAGR, generating a net total of $24995.5 million.

MARKET INSIGHTS

The global CGMS market is segmented on the basis of its component types and end users. The component types segment of the market includes sensors, transmitters and receivers, and insulin pump. The end users segment of the market includes home settings, diagnostics and clinics, and hospitals.

The global SMBG market is also segmented on the basis of its component types and end users. The component types segment of the market includes test strips, glucose meter, and lancets. The end users segment of the market includes home settings, clinics, and hospitals.

REGIONAL INSIGHTS

The regional segmentation of the markets is done into North America, Europe, Asia Pacific, Latin America, and rest of the world. The North American market is expected to capture the highest revenue share by 2026, for both CGMS and SMBG markets, driven by high awareness related to diabetes. Latin America and Asia-Pacific are predicted to grow more over the forecast period, owing to the increasing diabetic population in these regions.

COMPETITIVE INSIGHTS

Medtronic, Dexcom, Abbott, Johnson and Johnson, Insulet Corp, Tandem Diabetes Care, Echo Theraperutics Inc., Roche Diagnostics, Nemaura Medical Inc., Senseonics Inc., Glysens Inc., Terumo, Wockhardt, I-Sens Inc., Morpen Laboratories Ltd., Apex Biotechnology Corp., Arkray Inc., B Braun Melsungen AG, and Ascensia are some of the noted market players in the global glucose monitoring systems market.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE STUDY MARKET
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
  • 2.2. BOTTOM-UP APPROACH
  • 2.3. TOP DOWN APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. CGMS MARKET IS ANTICIPATED TO BE A DEVELOPED MARKET
    • 3.2.2. SELF-MONITORING OF BLOOD GLUCOSE HAS HUGE MARKET OPPORTUNITY
    • 3.2.3. COLLABORATION OF SIGNIFICANT COMPANIES TO DEVELOP INTEGRATED CGMS-ENABLED INSULIN PUMPS

4. MARKET OVERVIEW

  • 4.1. DRIVERS AND IMPACT
    • 4.1.1. RISE IN THE INCIDENCE OF DIABETES
    • 4.1.2. INCREASE IN HEALTHCARE EXPENDITURE
    • 4.1.3. INCREASING FOCUS ON RESEARCH AND DEVELOPMENT
    • 4.1.4. TECHNOLOGY INTEGRATION
    • 4.1.5. INCREASING CGMS AND SMBG AFFORDABILITY
    • 4.1.6. TECHNOLOGICAL ADVANCES IN GMS DEVICES
    • 4.1.7. AWARENESS AMONG THE GENERAL POPULATION
  • 4.2. RESTRAIN AND IMPACT
    • 4.2.1. HINDERANCE FROM GOVERNMENT REGULATIONS
    • 4.2.2. INADEQUATE REIMBURSEMENT OPTIONS FOR CONTINUOUS GLUCOSE MONITORING DEVICES
    • 4.2.3. LACK OF AWARENESS OF THE DIAGNOSTIC OPPORTUNITIES
  • 4.3. CHALLENGES
    • 4.3.1. INTENSE COMPETITION AMONG VENDORS
    • 4.3.2. INACCURACY IN READING OF GMS DEVICES
    • 4.3.3. INCREASINGLY STRINGENT GOVERNMENT REGULATIONS

5. CGMS MARKET SEGMENTATION

  • 5.1. MARKET BY COMPONENT TYPE 2018-2026
    • 5.1.1. SENSORS
    • 5.1.2. TRANSMITTERS AND RECEIVERS
    • 5.1.3. INSULIN PUMP
  • 5.2. MARKET BY END USERS 2018-2026
    • 5.2.1. HOME SETTINGS
    • 5.2.2. DIAGNOSTICS AND CLINICS
    • 5.2.3. HOSPITALS

6. SMBG MARKET

7. SMBG MARKET SEGMENTATION

  • 7.1. MARKET BY COMPONENT TYPE 2018-2026
    • 7.1.1. TEST STRIPS
    • 7.1.2. GLUCOSE METER
    • 7.1.3. LANCETS
  • 7.2. MARKET BY END USERS 2018-2026
    • 7.2.1. HOME SETTINGS
    • 7.2.2. CLINICS
    • 7.2.3. HOSPITALS

8. KEY ANALYTICS

  • 8.1. PORTER'S 5 FORCE ANALYSIS
    • 8.1.1. THREAT OF NEW ENTRANT
    • 8.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 8.1.3. BARGAINING POWER OF BUYERS
    • 8.1.4. BARGAINING POWER OF SUPPLIER
    • 8.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 8.2. MERGER AND ACQUISITIONS
  • 8.3. KEY BUYING CRITERIA
  • 8.4. KEY TRENDS
    • 8.4.1. DEVELOPMENT OF HIGH-QUALITY WEARABLE DEVICES
    • 8.4.2. MOBILE HEALTHCARE MAKING THE DEVICES MORE USER-FRIENDLY
    • 8.4.3. INCREASING EFFORTS TOWARDS SPREAD OF AWARENESS
    • 8.4.4. INCREASE IN NON-INVASIVE DEVICES
    • 8.4.5. ENERGY HARVESTING TECHNOLOGY FOR UNINTERRUPTED USAGE
  • 8.5. REGULATION OF BLOOD SUGAR
  • 8.6. INCIDENCE AND PREVALENCE OF DIABETES FOR VARIOUS COUNTRIES

9. REGIONAL ANALYSIS

  • 9.1. NORTH AMERICA
    • 9.1.1. THE US
      • 9.1.1.1. THE UNITED STATES HEALTH AND HEALTHCARE
      • 9.1.1.2. THE UNITED STATES PHARMACEUTICAL MARKET
    • 9.1.2. CANADA
      • 9.1.2.1. CANADA HEALTH AND HEALTHCARE
      • 9.1.2.2. CANADA PHARMACEUTICAL MARKET
      • 9.1.2.3. CANADA DIABETES MARKET
  • 9.2. EUROPE
    • 9.2.1. GERMANY
      • 9.2.1.1. GERMANY HEALTH AND HEALTHCARE
      • 9.2.1.2. GERMANY PHARMACEUTICAL MARKET
    • 9.2.2. THE UK
      • 9.2.2.1. THE UNITED KINGDOM HEALTH AND HEALTHCARE
      • 9.2.2.2. THE UNITED KINGDOM HEALTHCARE PROVISION
      • 9.2.2.3. THE UNITED KINGDOM PRIVATE SECTOR INVOLVEMENT
      • 9.2.2.4. THE UNITED KINGDOM PHARMACEUTICALS
    • 9.2.3. FRANCE
      • 9.2.3.1. FRANCE HEALTH AND HEALTHCARE
      • 9.2.3.2. FRANCE HEALTHCARE PROVISION
      • 9.2.3.3. MARKET TRENDS
    • 9.2.4. ITALY
      • 9.2.4.1. ITALY HEALTH AND HEALTHCARE
      • 9.2.4.2. ITALY HEALTHCARE PROVISION
      • 9.2.4.3. ITALY PHARMACEUTICAL MARKET
    • 9.2.5. SPAIN
      • 9.2.5.1. SPAIN HEALTH AND HEALTHCARE
      • 9.2.5.2. SPAIN HEALTHCARE PROVISION
      • 9.2.5.3. SPAIN PHARMACEUTICAL SERVICES
    • 9.2.6. RUSSIA
      • 9.2.6.1. RUSSIA HEALTH AND HEALTHCARE
      • 9.2.6.2. RUSSIA PHARMACEUTICAL SERVICES
    • 9.2.7. REST OF EUROPE (ROE)
  • 9.3. ASIA-PACIFIC (APAC)
    • 9.3.1. CHINA
      • 9.3.1.1. CHINA HEALTH AND HEALTHCARE
      • 9.3.1.2. CHINA PHARMACEUTICAL MARKET
      • 9.3.1.3. CHINA DIABETES MARKET
      • 9.3.1.4. MARKET TRENDS
    • 9.3.2. INDIA
      • 9.3.2.1. INDIA HEALTH AND HEALTHCARE
      • 9.3.2.2. INDIA REGULATORY CHANGES
      • 9.3.2.3. INDIA PHARMACEUTICAL MARKET
      • 9.3.2.4. INDIA DIABETES MARKET
    • 9.3.3. AUSTRALIA
      • 9.3.3.1. MARKET TRENDS
    • 9.3.4. JAPAN
      • 9.3.4.1. JAPAN HEALTH AND HEALTHCARE
      • 9.3.4.2. JAPAN PHARMACEUTICAL MARKET
      • 9.3.4.3. JAPAN DIABETES MARKET
      • 9.3.4.4. MARKET TRENDS
    • 9.3.5. SOUTH KOREA
      • 9.3.5.1. MARKET TRENDS
    • 9.3.6. INDONESIA
      • 9.3.6.1. MARKET TRENDS
    • 9.3.7. MALAYSIA
      • 9.3.7.1. MARKET TRENDS
    • 9.3.8. PHILIPPINES
      • 9.3.8.1. MARKET TRENDS
    • 9.3.9. THAILAND
      • 9.3.9.1. MARKET TRENDS
    • 9.3.10. VIETNAM
      • 9.3.10.1. MARKET TRENDS
    • 9.3.11. REST OF ASIA-PACIFIC (ROAP)
  • 9.4. LATIN AMERICA
      • 9.4.1.1. BRAZIL HEALTH AND HEALTHCARE
      • 9.4.1.2. BRAZIL PHARMACEUTICAL MARKET
      • 9.4.1.3. MEXICO HEALTH AND HEALTHCARE
      • 9.4.1.4. MEXICO PHARMACEUTICAL MARKET
  • 9.5. MIDDLE EAST AND AFRICA (MEA)

10. COMPETITIVE LANDSCAPE

  • 10.1. MEDTRONIC
    • 10.1.1. OVERVIEW
    • 10.1.2. PRODUCT PORTFOLIO
    • 10.1.3. STRATEGIC INITIATIVES
    • 10.1.4. SCOT ANALYSIS
  • 10.2. DEXCOM
    • 10.2.1. OVERVIEW
    • 10.2.2. PRODUCT PORTFOLIO
    • 10.2.3. STRATEGIC INITIATIVES
    • 10.2.4. SCOT ANALYSIS
  • 10.3. ABBOTT
    • 10.3.1. OVERVIEW
    • 10.3.2. PRODUCT PORTFOLIO
    • 10.3.3. STRATEGIC INITIATIVES
    • 10.3.4. SCOT ANALYSIS
  • 10.4. JOHNSON AND JOHNSON
    • 10.4.1. OVERVIEW
    • 10.4.2. PRODUCT PORTFOLIO
    • 10.4.3. STRATEGIC INITIATIVES
    • 10.4.4. SCOT ANALYSIS
  • 10.5. INSULET CORP
    • 10.5.1. OVERVIEW
    • 10.5.2. PRODUCT PORTFOLIO
    • 10.5.3. STRATEGIC INITIATIVES
    • 10.5.4. SCOT ANALYSIS
  • 10.6. TANDEM DIABETES CARE
    • 10.6.1. OVERVIEW
    • 10.6.2. PRODUCT PORTFOLIO
    • 10.6.3. STRATEGIC INITIATIVES
    • 10.6.4. SCOT ANALYSIS
  • 10.7. ECHO THERAPEUTICS INC
    • 10.7.1. OVERVIEW
    • 10.7.2. PRODUCT PORTFOLIO
    • 10.7.3. STRATEGIC INITIATIVES
    • 10.7.4. SCOT ANALYSIS
  • 10.8. ROCHE DIAGNOSTICS
    • 10.8.1. OVERVIEW
    • 10.8.2. PRODUCT PORTFOLIO
    • 10.8.3. STRATEGIC INITIATIVES
    • 10.8.4. SCOT ANALYSIS
  • 10.9. NEMAURA MEDICAL INC
    • 10.9.1. OVERVIEW
    • 10.9.2. PRODUCT PORTFOLIO
    • 10.9.3. STRATEGIC INITIATIVES
    • 10.9.4. SCOT ANALYSIS
  • 10.10. SENSEONICS INC
    • 10.10.1. OVERVIEW
    • 10.10.2. PRODUCT PORTFOLIO
    • 10.10.3. STRATEGIC INITIATIVES
    • 10.10.4. SCOT ANALYSIS
  • 10.11. GLYSENS INC
    • 10.11.1. OVERVIEW
    • 10.11.2. PRODUCT PORTFOLIO
    • 10.11.3. STRATEGIC INITIATIVES
    • 10.11.4. SCOT ANALYSIS
  • 10.12. TERUMO
    • 10.12.1. OVERVIEW
    • 10.12.2. PRODUCT PORTFOLIO
    • 10.12.3. STRATEGIC INITIATIVES
    • 10.12.4. SCOT ANALYSIS
  • 10.13. WOCKHARDT
    • 10.13.1. OVERVIEW
    • 10.13.2. PRODUCT PORTFOLIO
    • 10.13.3. STRATEGIC INITIATIVES
    • 10.13.4. SCOT ANALYSIS
  • 10.14. I-SENS INC
    • 10.14.1. OVERVIEW
    • 10.14.2. PRODUCT PORTFOLIO
    • 10.14.3. STRATEGIC INITIATIVES
    • 10.14.4. SCOT ANALYSIS
  • 10.15. MORPEN LABORATORIES LTD.
    • 10.15.1. OVERVIEW
    • 10.15.2. PRODUCT PORTFOLIO
    • 10.15.3. STRATEGIC INITIATIVE
    • 10.15.4. SCOT ANALYSIS
  • 10.16. APEX BIOTECHNOLOGY CORP.
    • 10.16.1. OVERVIEW
    • 10.16.2. PRODUCT PORTFOLIO
    • 10.16.3. SCOT ANALYSIS
  • 10.17. ARKRAY INC
    • 10.17.1. OVERVIEW
    • 10.17.2. PRODUCT PORTFOLIO
    • 10.17.3. STRATEGIC ANALYSIS
    • 10.17.4. SCOT ANALYSIS
  • 10.18. B BRAUN MELSUNGEN AG
    • 10.18.1. OVERVIEW
    • 10.18.2. PRODUCT PORTFOLIO
    • 10.18.3. SCOT ANALYSIS
    • 10.18.4. STRATEGIC ANALYSIS
  • 10.19. ASCENSIA
    • 10.19.1. OVERVIEW
    • 10.19.2. PRODUCT PORTFOLIO
    • 10.19.3. SCOT ANALYSIS
    • 10.19.4. STRATEGIC ANALYSIS
Back to Top
전화 문의
이용안내
 
BCC Research